Barrons.com
These 3 Stocks Are Healthcare Leaders. Bullish Charts Show It.
📈
AI Sentiment
Highly Positive
8/10
- Home
- ABT
as of 12-10-2025 3:44pm EST
$122.48
+$1.25
+1.03%
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Chart Type:
Time Range:
| Founded: | 1888 | Country: | United States |
| Employees: | N/A | City: | ABBOTT PARK |
| Market Cap: | 222.8B | IPO Year: | N/A |
| Target Price: | $146.61 | AVG Volume (30 days): | 6.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.96 | EPS Growth: | 141.97 |
| 52 Week Low/High: | $110.86 - $141.23 | Next Earning Date: | 01-21-2026 |
| Revenue: | $43,843,000,000 | Revenue Growth: | 6.37% |
| Revenue Growth (this year): | 7.56% | Revenue Growth (next year): | 7.96% |
AI-Powered ABT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.78%
70.78%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Abbott Laboratories (ABT)
Shroff Eric
Sell
Senior Vice President
ABT Nov 25, 2025
Avg Cost/Share
$128.02
Shares
1,586
Total Value
$203,042.57
Owned After
30,384
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Shroff Eric | ABT | Senior Vice President | Nov 25, 2025 | Sell | $128.02 | 1,586 | $203,042.57 | 30,384 |
Latest Abbott Laboratories News
ABT Breaking Stock News: Dive into ABT Ticker-Specific Updates for Smart Investing
Simply Wall St.
Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns
➖
AI Sentiment
Neutral
5/10
GlobeNewswire
DNA Diagnostics Market Projected to Surge by 66% to USD 21.69 Billion by 2030
📈
AI Sentiment
Highly Positive
8/10
24/7 Wall St.
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
📊
AI Sentiment
Positive
7/10
Zacks
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
📈
AI Sentiment
Highly Positive
8/10
StockStory
2 Mega-Cap Stocks with Promising Prospects and 1 Facing Challenges
📊
AI Sentiment
Positive
7/10
Compare ABT vs Leading Stocks
See how ABT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABT Abbott Laboratories - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.